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Abstract
Background: Hyperglycaemia-induced oxidative damage is a well-established factor implicated in the development
of diabetic cardiomyopathy (DCM) in diabetic individuals. Some of the well-known characteristics of DCM include
increased myocardial left ventricular wall thickness and remodelling that result in reduced cardiac efficiency. To
prevent this, an increasing number of pharmacological compounds such as N-acetyl cysteine (NAC) are explored for
their antioxidant properties. A few studies have shown that NAC can ameliorate hyperglycaemia-induced oxidative
damage within the heart. Hence, the objective of this review is to synthesise the available evidence pertaining to
the cardioprotective role of NAC against hyperglycaemia-induced oxidative damage and thus prevent DCM.
Methods: This systematic review protocol will be reported in accordance with the Preferred Reporting Items for
Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. We will perform a comprehensive
search on major databases such as EMBASE, Cochrane Library, PubMed and Google scholar for original research
articles published from January 1960 to March 2017. We will only report on literature that is available in English.
Two authors will independently screen for eligible studies using pre-defined criteria, and data extraction will be
done in duplicate. All discrepancies will be resolved by consensus or consultation of a third reviewer. The quality
of studies will be checked using Cochrane Risk of Bias Assessment Tool and The Joanna Briggs Institute (JBI) Critical
Appraisal tools for non-randomised experimental studies. Heterogeneity across studies will be assessed using
the Cochrane Q statistic and the inconsistency index (I2). We will use the random effects model to calculate
a pooled estimate.
Discussion: Although several studies have shown that NAC can ameliorate hyperglycaemia-induced oxidative
damage within the heart, this systematic review will be the first pre-registered synthesis of data to identify
the cardioprotective potential of NAC against hyperglycaemia-induced oxidative damage. This result will help
guide future research evaluating the cardioprotective role of NAC against DCM and better identify possible
mechanisms of action for NAC to prevent oxidative damage with a diabetic heart.
Systemic review registration: PROSPERO CRD42017055851.
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Background
Diabetes mellitus (DM) is a chronic metabolic disease that
is characterised by raised blood glucose levels. DM may
arise due to insufficient production of insulin by the pan-
creatic beta-cells and is termed type 1 DM or the inability
of the body to use the insulin it produces, which is known
as type 2 DM [1]. The latter is related to obesity and
represents approximately 90% of DM cases worldwide
[1]. The increased percentage of premature deaths
resulting from DM places a growing burden on
healthcare resources in low- and middle-income
countries such as South Africa [1]. For example, a
combination of DM and cardiovascular diseases (CVDs)
alone are estimated to contribute up to 24% of the 43%
disease burden caused by non-communicable diseases in
South Africa [2]. It is further known that almost 80% of
deaths in diabetic patients are caused by cardiovascular-
related complications [1, 3]. Although coronary artery
disease (CAD) is the major cause of cardiovascular com-
plications in diabetic patients, DM can also affect cardiac
structure and function in the absence of CAD, a condition
identified as diabetic cardiomyopathy (DCM) [4]. DCM is
a unique clinical entity that is characterised by impaired
myocardial substrate metabolism, left ventricular (LV)
hypertrophy and diastolic dysfunction [4–6]. At present,
there is no specific treatment for DCM; however, tra-
ditional treatment of heart failure and DM are the
preferred methods used to contain DCM [7].
First-line antidiabetic drugs such as metformin and
insulin can prolong the lives of diabetic patients by
lowering glucose levels and have been shown to display
cardioprotective properties [8–10]. However, long-term
exposure to persistent hyperglycaemia appears to limit
the cardioprotective effect of these drugs as shown by an
increasing number of CVD-related deaths within dia-
betic patients [11]. Current consensus is that hypergly-
caemia generates overproduction of free-radical species,
which leads to oxidative stress and subsequent myocar-
dial damage. Hyperglycaemic-induced oxidative stress is
believed to directly cause modifications in cardiac struc-
ture and function that may occur in the late stage of
DM [12]. Therefore, the proposed use of antioxidant
therapies to curb intracellular oxidative damage and en-
hance the effect of current antidiabetic agents is among
the leading hypothesis being tested to reduce the risk of
myocardial infarction in diabetic patients [13–19].
N-acetyl cysteine (NAC) has emerged as a strong
agent that is increasingly studied for its cardioprotective
properties [13–19]. NAC is well absorbed by the intes-
tine, and its supplementation presents strong antioxidant
properties that are essential in preventing oxidative
damage [20, 21]. NAC acts as a precursor to the synthe-
sis of glutathione, which is one of the most important
antioxidants. In experimental settings, NAC displays a
strong potential to ameliorate oxidative stress resulting
in reduced LV myocardial fibrosis and remodelling
within a diabetic state [22, 23]. Although increasing
studies are available on the cardioprotective properties
of NAC [13–24], none of them have delivered a system-
atic or meta-analysis on its effect in preventing
hyperglycaemia-induced oxidative damage that may
result in the development of DCM.
Objectives
The aim of this study is to systemically assess results of pub-
lished data and summarise the state of knowledge on the
cardioprotective potential of NAC against hyperglycaemia-
induced oxidative damage that may lead to the development
of DCM.
Methods
Study design
The preferred reporting system will follow PRISMA-P (Pre-
ferred Reporting Items for Systematic Review and Meta-
Analysis Protocols) 2015 guidelines (Additional file 1). This
protocol was registered with the International Pro-
spective Register of Systemic Reviews (PROSPERO):
CRD42017055851.
Search strategy
The following electronic databases, with the help of an
experienced librarian, will be searched from 1960,
roughly corresponding to the time NAC was discovered
to be an effective mucolytic agent [25], to March 2017:
EMBASE, Cochrane Library, PubMed and Google
scholar. The search will be based on key words and
Medical Subject Headings (MeSH) terms such as ‘N-
acetyl cysteine’, ‘diabetes mellitus’, ‘oxidative stress’ and
‘cardiovascular disease’, including corresponding
synonym and associated terms for each item (Additional
file 2). The search will be adopted to each database to
eliminate any inconsistencies or de-duplication of refer-
ences that may affect data extraction. References will be
managed using EndNote.
Study selection
In vitro and in vivo studies to be included are those that
report on the use of NAC in various cardiovascular
systems (either cardiac cells or animals) as monotherapy
or in combination with another antioxidant or a known
antidiabetic or cardioprotective agent to prevent or pro-
tect against (1) hyperglycaemia- or high glucose-induced
oxidative damage; (2) oxidative stress; and (3) DCM. In
addition, if available, studies reporting on the cardiopro-
tective effect of NAC in diabetic patients (clinical trials or
observational studies) of all ages will be included. In stu-
dies which have not yet reported the relevant outcome,
data will be classified in a systematic review as ongoing
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studies. Each study that is included is expected to have a
non-treated control group that received placebo. Types of
publications from which data will be screened include
original articles, editorials, letters, and articles from the
grey literature (e.g. pre-prints and conference procee-
dings), whilst narrative reviews will only be screened for
primary studies. The search will be restricted to studies
written in English.
Data extraction
Two investigators (P.V.D. and S.C.D.) will independently
review all relevant articles and identify eligible studies.
Disagreements or uncertainties will be resolved by con-
sensus, whilst in case of persistent disagreement, a third
reviewer will be consulted (B.B.N.). To extract relevant
data for this review, a structured form that contains the
following information will be created: first author’s
details (name and year of publication), country of origin,
type of study or model used, dose of NAC and of any
other combinational agent used, duration of treatment,
sample size (e.g. number of animals used per treatment
group), assays performed and statistical analysis method
used for each study. In addition, if any clinical trials are
involved, relevant information such as participants’ char-
acteristics, including age, gender, and diabetes profile
(baseline blood glucose levels) will be extracted and
recorded separately from the in vitro and in vivo data.
Different type of studies, including in vitro, in vivo
animals, healthy humans and diabetic humans will be
analysed separately. Information extracted will be
assessed to remove any duplicates that may exist. More-
over, the Covidence online tool [26] will be used to
facilitate the process of screening, data extraction and
analysis. The primary outcome of the study will be to
determine whether NAC administration can protect the
heart against hyperglycaemia-induced oxidative damage,
whereas the secondary outcome will be to assess
whether NAC administration can improve the efficacy of
current antidiabetic or cardioprotective agents in pro-
tecting the heart against hyperglycaemia-induced oxida-
tive damage.
Quality assessment
The Cochrane Risk of Bias Assessment Tool will only be
used to assess risk of bias in included Randomised Con-
trolled Trials [27]. This tool contains several domains,
including selection bias, performance bias, detection
bias, attrition bias, reporting bias and other bias that
may not be covered by the other domains. As explained
by Foster et al., each endpoint and the risk of bias will
be assessed individually to generate an overall score [28].
The Joanna Briggs Institute (JBI) Critical Appraisal tools
for use in JBI Systematic Reviews, which is a specific
checklist for non-randomised experimental studies, will
be used for quality assessment of other types of studies
[29]. This appraisal tool will assess the methodological
quality of each study to determine the extent to which it
addressed the possibility of bias in its design, conduct
and analysis. Furthermore, the strength of evidence will
be assessed and reported using the GRADE system [30].
GRADE addresses several apparent shortcomings of
existing models of evidence evaluation. This includes as-
sessment of methodological flaws within the component
studies, consistency of results across diverse studies, pre-
cision of effect estimates, risk of publication bias and
how effective the treatments have been shown to be.
Data synthesis and analysis
To establish the cardioprotective effects of NAC on
hyperglycaemic-induced oxidative damage, the adjusted
risk estimates and 95% confidence intervals (CIs) will be
calculated for each study. Adjusted risk estimates across
studies will be pooled using random effects models with
inverse variance weighting as recommended in the
Cochrane handbook [31]. For synthesis, when studies
cannot be combined for meta-analysis due to diversity of
interventions, narrative synthesis will be conducted fol-
lowing guidelines by Popay et al. [32]. Inconsistency in the
cardioprotective effects of NAC across different studies
(heterogeneity) will be assessed using Cochrane Q statistic
and the inconsistency index (I2) [33], with an I2 statistic of
0 and 50% indicating no heterogeneity and moderate
heterogeneity, respectively. In addition to overall effect
assessment, subgroup and sensitivity analyses will be con-
ducted for types of participants (healthy patients or such
with DM) for included human studies. Furthermore, stu-
dies evaluating NAC monotherapy groups will be analysed
separately from studies specifically evaluating NAC com-
bination therapy groups. All analyses will be conducted
using Cochrane Review Manager 5.3 [34].
Discussion
This systemic review will assess the cardioprotective inter-
vention of NAC against diabetes-associated complications.
We will specifically focus on reviewing literature on the
protective potential of NAC against hyperglycaemia-
induced oxidative damage related to the development of
DCM. The proposal is made that persistent hypergly-
caemia and resultant oxidative stress directly cause
myocardial LV wall thickness and structural remodel-
ling leading to diastolic dysfunction within a diabetic
state [4–6, 12]. These are all conspicuous signs of
DCM and are experimentally targeted by various
pharmaceutical interventions in order to prolong the
lives of diabetic individuals [35, 36].
Accumulative data is increasingly reporting on the car-
dioprotective properties of various pharmacological
products in the treatment and prevention of DM and its
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complications [35–38]. Recently, our group has explored
phytochemical compounds for their protective effect
against DCM in cultured cardiomyocytes and diabetic
mice [37–40]. Data from these studies has demonstrated
that the antioxidant properties from these bioactive com-
pounds when used either alone or in combination with
metformin are important in combating hyperglycaemia-
induced oxidative damage. Therefore, this has led us to
hypothesise that nutraceuticals and pharmacological com-
pounds with strong antioxidant properties such as NAC
may be the key in preventing hyperglycaemia-induced oxi-
dative damage within the heart and improving the lives of
diabetic individuals. To date, several studies have already
assessed the protective activity of NAC against DCM-
associated complications [13–24]; however, none have
delivered an extensive overview about the topic.
In summary, this systemic review will address the
existing knowledge gap regarding the protective effect of
NAC against DCM, in particular, for the prevention of
hyperglycaemia-induced oxidative damage. An extensive
synthesis of the available data will permit identification
of evidence gaps. Furthermore, since NAC is already
listed in the World Health Organisation’s list of essential
medicines, this review may determine whether more re-
search is necessary to establish its use as a protective
therapy against DCM.
Additional files
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